Fostamatinib, as a Syk inhibitor, has been approved by the FDA to treat immune thrombocytopenia, but clinical trials studying its efficacy and safety in LAM treatment still wait to be accomplished. The gene discussed is SYK; the disease is lymphangioleiomyomatosis.